Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) will undergo a 1-for-25 reverse stock split of its common stock on February 5, 2026, to maintain listing compliance on the Nasdaq. The reverse split will reduce outstanding shares from 27.8 million to 1.1 million, with no change to authorized shares. The move aims to attract more institutional and retail investors by increasing the bid price to at least $1.00 per share. CEO Cary Claiborne sees this as a crucial step to strengthen market presence and advance AD04, a potential treatment for Alcohol Use Disorder and other addictive disorders. Shareholders will receive instructions for exchanging stock certificates from VStock Transfer, LLC. For more information, visit www.adial.com.

Read more at GlobeNewswire: Adial Pharmaceuticals Announces Reverse Stock Split to